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Five candidateplasmabiomarkers (suppressionof tumorogenesis 2 [ST2], regenerating islet-derived-3a [REG3a],
elaﬁn, tumor necrosis factor receptor 1 [TNFR1], and soluble IL-2 receptor-alpha [sIL2Ra]) were measured at
speciﬁc timepoints after cyclophosphamide/ﬂudarabine-basednonmyeloablative allotransplantation (NMAT) in
patients who did or did not develop acute graft-versus-host disease (aGVHD). Plasma samples from 34 patients
were analyzed at days þ7, þ14, þ21, and þ30. At a median follow-up of 358 days, 17 patients had experienced
aGVHD with a median time to onset at day þ36. Risk of aGVHD was associated with elevated plasma ST2 con-
centrations at dayþ7 (c-statistic¼ .72, P¼ .03), dayþ14 (c-statistic¼ .74, P¼ .02), and dayþ21 (c-statistic¼ .75,
P ¼ .02); elevated plasma REG3a concentrations at dayþ14 (c-statistic¼ .73, P ¼ .03), dayþ21 (c-statistic ¼ .76,
P¼ .01), and dayþ30 (c-statistic¼ .73, P¼ .03); and elevated elaﬁn at dayþ14 (c-statistic¼ .71, P¼ .04). Plasma
concentrations of TNFR1 and sIL2Ra were not associated with aGVHD risk at any of the time points studied.
This study identiﬁed ST2, REG3a, and elaﬁn as prognostic biomarkers to evaluate risk of aGVHD after
cyclophosphamide/ﬂudarabine-based NMAT. These results need to be conﬁrmed in an independent validation
cohort.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Acute graft-versus-host disease (aGVHD) continues to be
a major contributor to early transplant-related mortality
after allogeneic hematopoietic cell transplantation. There is
no reliable way to determine before the onset of symptoms
who will suffer complications. To date, the choice of
candidate biomarkers for aGVHD has been guided by
studies performed in groups of patients who received
myeloablative full or reduced-intensity conditioning. We
previously demonstrated that a biomarker panel consisting
of IL-2 receptor-alpha (IL2Ra), tumor necrosis factor
receptor-1 (TNFR1), IL-8, and hepatocyte growth factor
correlated with clinical diagnosis of aGVHD as well as sur-
vival, independent of clinical grade severity. A panel of 6
biomarkers predicted treatment response and survival after
aGVHD [1,2]. Recently, the suppression of tumorogenesis 2
(ST2) was identiﬁed as a novel marker useful in predicting
glucocorticoid-resistant aGVHD and nonrelapse mortality
(NRM) [3].Nonmyeloablative allotransplantation (NMAT) condi-
tioning extends allotransplant options to older individuals
who may be at higher risk for aGVHD on the basis of age;
NMAT, a minimally intense RIC is associated with low
incidences of early transplant-related complications and
mortality. Cyclophosphamide (Cy) and ﬂudarabine (Flu)
based NMATenables engraftment in recipients of related and
unrelated HLA-matched grafts without mucositis and/or
sinusoidal obstructive syndrome [4,5]. The validation of
biomarkers across a variety of settings is critical before
attempting to integrate their use in clinical practice. We
conducted a study to test the ability of plasma levels of 5
individual biomarkers at speciﬁc time points to serve as
prognostic markers for aGVHD among patients undergoing
Cy/Flu-based NMAT.METHODS
Patient Population
Thirty-four patients with hematological malignancies who underwent
Cy/Flu-based NMAT at Indiana University between 2008 and 2012 were
included in the study, which was approved by the Indiana University
institutional review board. Disease status at transplant was categorized
according to the American Society of Blood and Marrow Transplantation
criteria [6].
Patients received mobilized peripheral blood hematopoietic cells from
matched relatedormatchedunrelateddonors.GVHDprophylaxis formatched
unrelated donor recipients consisted of cyclosporine A  mycophenolate
mofetil or basiliximab (NCT00975975) or a combination of tacrolimus and
sirolimus. Matched related recipients received a combination of cyclosporine
A  mycophenolate mofetil or basiliximab. Patients were followed prospec-
tively until death or for a median of 358 days (range, 182 to 1381 days) and
Table 1
Patient Characteristics
Total
(N ¼ 34)
aGVHDþ
(n ¼ 17)
No aGVHD
(n ¼ 17)
Median age, yr (range) 60 (29-72) 61 (29-72) 59 (33-66)
Diagnosis
Acute leukemia 14 8 6
Chronic leukemia 5 4 1
MDS/MF 9 3 6
NHL 4 1 3
HD 2 1 1
Donor
Related 16 4 12
Unrelated 18 13 5
Match
Fully matched 32 15 17
Mismatched 2 2 0
GVHD prophylaxis
Cyclosporine A/basiliximab 16 10 6
Tacrolimus/sirolimus 15 6 9
Cyclosporine A/mycophenolate
mofetil
3 1 2
ASBMT status*
Low risk 11 5 6
Intermediate risk 14 8 6
High risk 8 3 5
MDS indicates myelodysplastic syndrome; MF, myeloﬁbrosis; NHK, non-
Hodgkin lymphoma; HD, Hodgkin disease; ASBMT, American Society of
Blood and Marrow Transplantation.
* Not applicable for one subject with myeloﬁbrosis.
Table 2
aGVHD Grade at Onset and at Maximum
aGVHD Grade
I II III IV
At onset
Overall 3 9 5 0
Skin 1 4 3 0
GI 6 1 4 0
Liver 2 2 1 0
At maximum
Overall 2 5 8 2
Skin 0 3 6 0
GI 3 1 6 2
Liver 2 3 1 0
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were used to diagnose and grade aGVHD at onset and at maximum severity
[7]. Histopathological conﬁrmation of aGVHD was obtained whenever clini-
cally feasible.
Sample Preparation and Processing
Ten to 20 mL of whole blood was obtained from patients on
days þ7, þ14, þ21, and þ30 in heparin-containing tubes to prevent clotting.
Plasma was obtained from blood samples by centrifugation. Samples were
aliquoted without additives into cryovials and stored at 80C.
Five plasma biomarkers were studied: ST2, regenerating islet-derived-
3a (REG3a), elaﬁn, TNFR1, and soluble IL2Ra (sIL2Ra). Plasma ST2, elaﬁn, and
TNFR1 levels were measured by ELISA using commercially available kits
(DST200, DY1747, and DY225, respectively; R&D Quantikine, Minneapolis,
MN). Plasma REG3a was measured using ELISA kit 5323 (MBL International
Corp., Woburn, MA), and sIL2Ra was measured using a commercially
available multiplex platform (MPXHCYTO-60K; Millipore Corp., Billerica,
MA). All assays were performed in compliance with protocols provided by
kit manufacturers.
Statistical Analysis
Differences in patient characteristics between aGVHDþ and no aGVHD
groups were determined using Wilcoxon rank sum test for age at transplant
and Fisher’s exact test for all categorical variables. Medians and 25th and
75th percentiles of individual biomarker levels in aGVHDþ and no aGVHD
groups were calculated and distributions compared at each time point using
exact Wilcoxon rank sum tests (because of non-normality of biomarkers),
and corresponding c-statistics, which represent the area under the receiver
operating characteristic curves, were calculated by ﬁtting logistic regressionTable 3
Biomarker Medians (25th and 75th percentile in parentheses) by Group Over Tim
Day þ7
aGVHDþ No aGVHD c-st
ST2, ng/mL 73.2 (25.9, 149.2) 25.7 (12.9, 42.7) .72
Reg3a, pg/mL 51.4 (24.2, 93.5) 40.5 (20.0, 53.2) .63
Elaﬁn, pg/mL 7628.3 (4303.0, 18557.2) 5088.0 (3530.3, 8057.8) .62
TNFR1, pg/mL 4348.9 (2408.7, 6562.1) 3747.1 (2025.1, 4341.2) .62
sIL2Ra, pg/mL 883.2 (254.6, 1673.0) 137.5 (50.1, 481.0) .70
* For ST2, Reg3a, elaﬁn, and TNFR1, sample sizes were 17, 16, 17, and 16 for aGV
respectively. For sIL2Ra, sample sizes were 12, 10, and 10 for aGVHDþ and 10, 13,models. Biomarkers with statistically signiﬁcant prognostic value were
further analyzed to determine their ability to predict grades III to IV or
gastrointestinal (GI)-speciﬁc aGVHD (versus no aGVHD using exact Wil-
coxon test). Association of elevated (median or higher) biomarker levels
with overall survival and NRM was determined using log-rank test and
Gray’s test. P .05was considered to be the criteria of statistical signiﬁcance.
All statistical analyses were performed in SAS version 9.3 (SAS Institute,
Cary, NC).RESULTS
Of 34 patients included in the study, 17 experienced
aGVHD and 17 did not. Table 1 describes patient character-
istics. Age, diagnosis, match, GVHD prophylaxis, and Amer-
ican Society of Blood and Marrow Transplantation risk did
not differ between aGVHDþ and no aGVHD groups (P> .16 for
each). Patients who received grafts from an unrelated donor
developed aGVHD more frequently (76% versus 24%;
P¼ .015). Median onset of aGVHDwas dayþ36 (range,þ17 to
151). Table 2 describes the overall and site-speciﬁc severity of
aGVHD at onset and at maximum clinical grade according to
modiﬁed Glucksburg criteria. Of 17 patients who experi-
enced aGVHD, 9 had skin, 12 had GI, and 6 had liver
involvement.
Table 3 shows the median and 25th and 75th percentiles
of plasma biomarker concentrations in aGVHDþ and no
aGVHD groups at speciﬁc time points after hematopoietic
cell transplantation and corresponding c-statistics and
P values. Elevated plasma ST2 levels at daysþ7,þ14, andþ21
were signiﬁcant risk factors for aGVHD occurrence
(Figure 1A). Similarly, plasma REG3a levels at days þ14, þ21,
and þ30 were also signiﬁcantly elevated among aGVHDþ
patients (Figure 1B). Elevated plasma elaﬁn levels at dayþ14
were also associated with aGVHD. When ST2 and REG3a
were considered together in a logistic regression model, the
corresponding c-statistics were .68 at day þ7, .77 at dayþ14,
.75 at day þ21, and .74 at day þ30.
We compared sIL2Ra levels using exact Wilcoxon tests in
patients who received or did not receive basiliximab. Thosee*
Day þ14
atistic P aGVHDþ No aGVHD
.03 53.8 (26.8, 95.9) 19.8 (14.4, 42.3)
.20 194.8 (46.7, 825.0) 50.3 (23.6, 72.9)
.26 10156.8 (5531.0, 14428.2) 4610.0 (3416.2, 8140.6)
.23 5695.1 (2946.4, 9701.1) 3809.8 (2391.9, 4935.8)
.14 269.1 (26.1, 3051.3) 95.7 (83.8, 265.3)
HDþ and 17, 15, 15, and 16 for no aGVHD for days þ7, þ14, þ21, and þ30,
and 14 for no aGVHD for days þ7, þ14, and þ21 respectively.
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day þ7 (P ¼ .003), lower values on day þ14 (P ¼ .02), and no
difference in values on day þ21 (P ¼ .27).
The difference of day þ14 biomarker levels between
grades III to IV aGVHDþ and no aGVHD was not statistically
signiﬁcant:median ST2 34.0 and 19.8 ng/mL (P¼ .10), median
REG3a 180.9 and 50.3 pg/mL (P ¼ .07), and median elaﬁn
7818.1 and 4610.0 pg/mL (P ¼ .07), respectively. The differ-
ence of day þ14 REG3a levels between GI aGVHDþ and no
aGVHD also did not reach statistical signiﬁcance: median
208.7 versus 50.3 pg/mL (P ¼ .08).
Elevated (50th percentile) biomarker levels at day þ14
were not associated with overall survival: ST2 median 792
versus 442 days (log-rank P ¼ .824), REG3a 792 versus
442 days (P ¼ .558), and elaﬁn 1081 versus 545 days
(P ¼ .582). Similarly, elevated biomarker levels at day þ14
were also not associated with NRM.Figure 1. (A) ST2 (ng/mL) levels over time for individual patients in aGVHDþ
and no aGVHD groups. (B) REG3a (pg/mL) levels over time for individual
patients in aGVHDþ and no aGVHD groups.DISCUSSION
This study was conducted to determine prognostic
plasma biomarkers for aGVHD after Cy/Flu-based NMAT. ST2,
REG3a, and elaﬁn levels were elevated at certain time points
in patients who developed aGVHD versus those who did not.
These were, however, not signiﬁcant prognostic biomarkers
for other endpoints, including grades III to IV aGVHD, overall
survival and NRM, possibly because sample size of the study
was not powered for these endpoints.
The choice of biomarkers to consider was based on pre-
vious ﬁndings in cohorts undergoing myeloablative allo-
transplantation [2,3,8,9]. REG3a is secreted by Paneth cells
into intestinal crypts and reduces inﬂammation, protects
intestinal stem cells, and prevents GI epithelial damage [10].
REG3a does not mediate aGVHD but appears to protect
damaged epithelium. It is a biomarker for GVHD of the GI
tract and a predictor of NRM [11]. Dayþ14 REG3a levels were
not statistically higher in patients with GI aGVHD compared
with no aGVHD, which we believe is attributable to the
relatively small number of patients in this study. Elaﬁn is
associated with severity and mortality from aGVHD of the
skin [8]. As part of a panel consisting of 6 biomarkers, REG3a
and elaﬁn predicted treatment response and survival from
aGVHD [2]. ST2 in its soluble form acts as a negative regulator
of type 2 helper T cells [12]. ST2 was recently identiﬁed as a
marker that predicted glucocorticoid-resistant aGVHD and
NRM [3].
In the present study, it is noteworthy that we did not ﬁnd
TNFR1 or sIL2Ra elevated in those who developed aGVHD
and elaﬁn was signiﬁcantly elevated at only day þ14. The
relatively small sample size might not yield sufﬁcient power
to detect the prognostic value of all relevant biomarkers.
Also, the use of prognostic markers identiﬁed in the setting
of higher intensity conditioning might not be applicableDay þ14 Day þ21
c-statistic P aGVHDþ No aGVHD c-statistic
.74 .02 28.3 (18.8, 143.9) 16.2 (12.5, 23.7) .75
.73 .03 178.1 (54.0, 649.5) 41.7 (29.6, 64.6) .76
.71 .04 7793.0 (4610.0, 10586.5) 5931.4 (3916.6, 10941.0) .54
.64 .20 5443.2 (3974.0, 6784.1) 4528.0 (2692.6, 5492.5) .67
.61 .41 930.5 (194.3, 2098.1) 216.6 (167.4, 398.1) .68
Table 3
(continued)during Cy/Flu-based NMAT. Finally, it is plausible that using
basiliximab (given at day þ7, þ8, or þ9) as part of GVHD
prophylaxis for some patients led to lower levels of day þ14
sIL2Ra and confounded results; subset analysis among pa-
tients not receiving basiliximab was not done because of the
relatively small number of patients. The higher level of
sIL2Ra at day þ7 was obtained before basiliximab adminis-
tration, when cyclosporine was the only immunosuppressive
present in the circulation.
Biomarkers are most valuable if they identify patients at
high risk of an adverse outcome before the clinical signs are
apparent. This could potentially provide clinicians with suf-
ﬁcient time to institute appropriate interventions before
signiﬁcant tissue damage has occurred and hopefully avert
the adverse outcome. For instance, patients at high risk ofDay þ30
P aGVHDþ No aGVHD c-statistic P
.02 26.3 (10.3, 134.4) 15.0 (11.2, 22.0) .68 .09
.01 130.6 (52.5, 605.2) 51.4 (30.1, 87.8) .73 .03
.74 6987.6 (5355.0, 12224.5) 8794.1 (5786.9, 15783.8) .57 .45
.11 4421.9 (3261.4, 7989.6) 4094.6 (3150.5, 5572.2) .49 .33
.13
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tively. Among biomarkers identiﬁed in current study, only
ST2 was prognostic of aGVHD risk before day þ14 after he-
matopoietic cell transplantation; this is not surprising given
the relatively late (median, 36 days) onset of aGVHD after
NMAT. Clinically relevant prognostic tools proposed in prior
studies consisted of a panel rather than a single biomarker;
therefore, combinations of biomarkers need to be explored
further [1,2,9].
In conclusion, the current study identiﬁed ST2, REG3a,
and elaﬁn as prognostic biomarkers to stratify for risk of
developing aGVHD after Cy/Flu-based NMAT. These results
need to be conﬁrmed in a large independent validation
cohort, ideally among a number of institutions, to establish
clinically useful cut-offs for their future use in clinical trials.
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Brentuximab vedotina b s t r a c t
We previously reported that brentuximab vedotin (BV) enabled successful reduced-intensity allogeneic he-
matopoietic cell transplantation (RIC-alloHCT) in patients with relapsed Hodgkin lymphoma, after a median
follow-up of 14.4 months. We now provide an updated report on 21 patients who were treated from 2009 to
2012 with BV before RIC-alloHCT with a uniform ﬂudarabine/melphalan conditioning regimen and donor
source after a median follow-up of 29.9 months. We have also retrospectively compared the patient char-
acteristics and outcomes of these BV-pretreated patients to 23 patients who received ﬂudarabine/melphalan
RIC-alloHCT without prior BV, in the time period before the drug was available (2003 to 2009). Patients who
were treated with BV before RIC-alloHCT had a lower median hematopoietic cell transplantationespeciﬁc
comorbidity index and a reduced number of peri-transplantation toxicities. There were also improvements in
2-year progression-free survival (59.3% versus 26.1%) and cumulative incidence of relapse/progression (23.8%
versus 56.5%).
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Brentuximab vedotin (BV) is an antibody-drug conjugate of
anti-CD30 antibody and the microtubule-disrupting agent,
monomethyl auristatin E [1]. BV is approved for use in Hodgkin
lymphoma (HL) patients who have failed autologous hemato-
poietic cell transplantation (autoHCT). Phase II studies report
